ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that a new subgroup analysis of its ongoing phase 2 pilot PANOVA clinical trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 3-7, 2016, demonstrating an overall survival benefit in advanced pancreatic cancer patients treated with Tumor Treating Fields (TTFields) combined with gemcitabine compared to historical controls of gemcitabine alone.
